to concerns about teratogenicity, it is optimal to allow adequate time for observation of disease stability without medication. For women treated with leflunomide, we strongly recommend cholestyramine washout if there are detectable serum levels of metabolite prior to or as soon as pregnancy is confirmed. Once metabolite is not detectable in the serum, the risks of pregnancy loss and birth defects are not elevated We conditionally recommend treatment with CYC for life-threatening conditions in